Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517722 | 0.98 | SIGMAR1 (0.51) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL17528477 | 0.96 | SIGMAR1 (0.50) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL14385506 | 0.94 | SIGMAR1 (0.47) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL791946 | 0.89 | SIGMAR1 (0.58) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL18024078 | 0.88 | SIGMAR1 (0.47) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL18024037 | 0.88 | SIGMAR1 (0.47) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL17539606 | 0.87 | SIGMAR1 (0.60) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL18024082 | 0.86 | SIGMAR1 (0.49) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL11717752 | 0.86 | SIGMAR1 (0.48) | SIGMAR1CYP1A2 | |
| SCHEMBL17528497 | 0.86 | SIGMAR1 (0.44) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115243789-A | Catalyst composition for polyurethane | 迈图高新材料公司 | 2022-10-25 | — | — | CN | claimed |
| US-20230151136-A1 | CATALYST COMPOSITION FOR POLYURETHANES | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151136-A1 | CATALYST COMPOSITION FOR POLYURETHANES | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230134280-A1 | CATALYSTS FOR THE FORMATION OF POLYURETHANES | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115243789-A | Catalyst composition for polyurethane | 迈图高新材料公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2016130968-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | YALE UNIVERSITY (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | SIGMAR1 3155/4885SLC6A4 4166/4885SLC6A3 2991/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | SIGMAR1 3155/4885SLC6A4 4166/4885SLC6A3 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.